Merck: Dividend Near A 12-Year High, But I Won't Buy - Here's Why:
Merck offers a 4.2% dividend yield but faces uncertainty with KEYTRUDA's LOE ...
seekingalpha.com/article/4789465-merck-dividend-near-a-12-year-high-but-i-wont-buy-heres-why
Paid articlePaywallStory Details
| Last Updated | |
| Total Articles | 3 |
Main Topics
News on this topic
Merck: Defensive Yield Meets Long-Term Optionality: Merck is expanding in oncology, immunology, and vaccines through acquisitions and R&D ...
seekingalpha.com/article/4789462-merck-defensive-yield-meets-long-term-optionality
Paid articlePaywall Merck & Co. Stock: Inventory Doesn't Lie: Discover why Merck stock (MRK) faces a downgrade amid rising inventories, Gardasil challenges ...
seekingalpha.com/article/4789165-merck-stock-inventory-doesnt-lie
Paid articlePaywallSimilar to This
Previous
The drug that blows everything up: No drug in the world costs as much as the cancer therapy Keytruda. Yet there are certainly ways to reduce these costs.
republik.ch/2026/04/13/das-medikament-das-alles-sprengt
Surprising quarterly figures: Pharma giants disappoint investors despite growth: Merck and Pfizer surprise with quarterly figures. But strong growth at Keytruda ...
wallstreet-online.de/nachricht/20448941-aktien-fallen-trotzdem-ueberraschende-quartalszahlen-pharma-riesen-enttaeuschen-anleger-trotz-wachstum
Merck to scrap London drug research centre: Merck said on Wednesday it was scrapping research operations in London, citing the UK's challenging business ...
reuters.com/business/healthcare-pharmaceuticals/merck-scrap-london-drug-research-centre-2025-09-10/
Merck: Buy The Weakness: Merck trades at a low P/E with strong financials, Keytruda growth, and a solid 3.9% yield, while its pipeline offsets future risks ...
seekingalpha.com/article/4814259-merck-buy-weakness
Paid articlePaywall Merck & Co., Inc. (MRK) Presents at HIV Investor Event Transcript: Merck & Co., Inc. (NYSE:MRK) HIV Investor Event July 17, 2025 9:00 AM ETCompany ...
seekingalpha.com/article/4802101-merck-and-co-inc-mrk-presents-at-hiv-investor-event-transcript
Merck Proves Why It's Still A Top Pharma Pick: Merck beats Q1 2025 estimates despite Gardasil sales drop, driven by Vaxneuvance, Winrevair & Welireg.
seekingalpha.com/article/4790266-merck-proves-why-its-still-a-top-pharma-pick
Paid articlePaywall Merck & Co.: Looming Patent Expiries For Key Drugs Weakens Longer-Term Outlook: >40% of Merck's revenues are driven by cancer med Keytruda, which faces patent ...
seekingalpha.com/article/4770534-merck-and-co-looming-patent-expiries-for-key-drugs-weakens-longer-term-outlook
Paid articlePaywall Merck & Co., Inc. (MRK) Jefferies London Healthcare Conference: Merck & Co., Inc. (NYSE:MRK) Jefferies London Healthcare Conference November 21 ...
seekingalpha.com/article/4739369-merck-and-co-inc-mrk-jefferies-london-healthcare-conference
Merck Among 10 Companies To Announce Annual Dividend Increases In Second Half Of November
seekingalpha.com/article/4738287-merck-among-10-companies-announce-annual-dividend-increases-h2-november
Paid articlePaywall Merck: An Undervalued Dividend Machine: Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its ...
seekingalpha.com/article/4734237-merck-an-undervalued-dividend-machine
Paid articlePaywall Merck & Co., Inc. (MRK) Q3 2024 Earnings Conference Call Transcript: Start Time: 09:00 January 1, 0000 10:00 AM ETMerck & Co., Inc.
seekingalpha.com/article/4731598-merck-and-co-inc-mrk-q3-2024-earnings-conference-call-transcript
MSD: Very High, Fully-Covered Yield But No EM Currency Exposure: MS Emerging Markets Debt Fund offers a high yield of 11.44%, providing income-focused investors ...
seekingalpha.com/article/4719383-msd-very-high-fully-covered-yield-but-no-em-currency-exposure
Paid articlePaywall Merck's Change To Profit Guidance Provides An Opportunity: Merck's reduced profit guidance is primarily due to recent acquisitions, but the company remains ...
seekingalpha.com/article/4718394-mercks-change-to-profit-guidance-provides-an-opportunity
Paid articlePaywall Merck: Among The Best Health Care GARP Plays Today: Merck offers strong forward earnings growth trends and a compelling current valuation ...
seekingalpha.com/article/4702277-merck-stock-mrk-among-best-health-care-garp-plays-today
Paid articlePaywall Dividends And Innovation: Why Merck Is A Healthcare Stock Worth Buying: Merck has a highly favorable growth outlook and an attractive dividend growth profile ...
seekingalpha.com/article/4698388-dividends-and-innovation-why-merck-is-a-healthcare-stock-worth-buying
Paid articlePaywall Merck Stock: Still Discounted To Graham P/E: Merck's well-balanced business model, the Keytruda franchise, and superb financial strength further skew the ...
seekingalpha.com/article/4696265-merck-stock-still-discounted-to-graham-pe
Paid articlePaywall Merck & Co., Inc. (MRK) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)
seekingalpha.com/article/4677724-merck-and-co-inc-mrk-presents-barclays-26th-annual-global-healthcare-conference-transcript
Parker-Hannifin Corporation (PH) Q2 2024 Earnings Call Transcript: Parker-Hannifin Corporation (NYSE:NYSE:PH) Q2 2024 Earnings Conference Call February 1 ...
seekingalpha.com/article/4666804-parker-hannifin-corporation-ph-q2-2024-earnings-call-transcript
Merck & Co., Inc. (MRK) JPMorgan 42nd Annual Healthcare Conference (Slides): The following slide deck was published by Merck & Co., Inc.
seekingalpha.com/article/4661842-merck-and-co-inc-mrk-jpmorgan-42nd-annual-healthcare-conference-slides
Paid articlePaywall Next